Kentucky Accuses Endo of Contributing to Opioid Epidemic

(Reuters)—Kentucky accused units of Endo International Plc. on Monday of contributing to drug overdoses by deceptively marketing its painkiller Opana ER, in the latest lawsuit by state or local governments against the drugmaker amid an opioid epidemic.

You Might Also Like

Kentucky Attorney General Steve Beshear said the lawsuit would seek to hold Endo responsible for illegally building a market for the long-term use of opioids in the state as part of an effort to boost corporate profits.

ad goes here:advert-1

ADVERTISEMENT

SCROLL TO CONTINUE

The lawsuit, filed in a state court in Kentucky, claims Endo sought to overstate the benefits of using Opana for the long-term treatment of chronic pain while downplaying the risk of addiction, helping to fuel a public health epidemic.

“My office refuses to sit back and watch families be torn apart while opioid manufacturers like Endo line their pockets at the expense of our communities and our future,” Beshear said in a statement.1

ad goes here:advert-2

ADVERTISEMENT

SCROLL TO CONTINUE

Endo did not immediately respond to a request for comment. It has previously said that it considers ensuring patient safety a top priority.

Endo has faced a wave of similar lawsuits over the opioid epidemic by Louisiana, New Mexico, Missouri, Mississippi and Ohio, as well as several cities and counties. Many of those cases target other drugmakers.

ad goes here:advert-3

ADVERTISEMENT

SCROLL TO CONTINUE

In July, Endo agreed to withdraw the long-acting opioid painkiller Opana ER from the market after the U.S. Food and Drug Administration declared that its benefit did not outweigh public health risks associated with opioid abuse.

In a statement, Beshear called the removal of Opana ER from the market an important step but said that Endo’s practices had already by then harmed people in his state. His office’s lawsuit seeks penalties and compensatory and punitive damages.

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.